X

Trial Profile

A first-in-human study of BOXR1030

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BOXR 1030 (Primary)
Indications Liver cancer; Lung cancer; Merkel cell carcinoma; Myxoid liposarcoma; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Acronyms DUET-01

Most Recent Events

24 Apr 2024 According to a SOTIO media release, the company will present a Trial-in-Progress poster on the DUET-01 Phase 1/2 study of BOXR1030 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024, in Chicago, IL.
18 Nov 2022 New trial record
10 Nov 2022 According to a SOTIO media release, the company plans initiate this study in coming months

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com